Immunitybio announces uk medicines and healthcare products regulatory agency accepted marketing authorization application for anktiva® for the treatment of patients with bcg-unresponsive non-muscle invasive bladder cancer carcinoma in situ

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunity therapy company, today announced the medicines and healthcare products regulatory agency (mhra) has validated and accepted the marketing authorization application for anktiva. the mhra will now begin assessing the marketing authorization application (maa) for anktiva® (nogapendekin alfa inbakicept-pmln) in combination with bacillus calmette-guÉrin (bcg) for the treatment of patients with bcg-unresponsive.
IBRX Ratings Summary
IBRX Quant Ranking